ASH 2023 | MRD status predicts alloSCT outcomes in NPM1-mutated AML: an analysis of AML17 and AML19 studies
Jad Othman, MBBS, King’s College and Guy’s & St Thomas’ NHS Foundation Trust, London, UK, discusses an analysis of the AML17 (ISRCTN55675535) and AML19 (ISRCTN78449203) trials, which indicates that allogeneic stem cell transplantation (alloSCT) at first remission confers benefits to survival outcomes in NPM1-mutated acute myeloid leukemia (AML) only in those patients who are measurable residual disease (MRD) positive, regardless of other risk factors such as FLT3 mutations. This supports the use of MRD-guided decision-making for alloSCT. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
